Review examines how biology may refine pancreatic cancer surgery decisions
The authors describe established and emerging markers of tumor behavior, while emphasizing that many still need prospective validation before routine clinical use.
Moderate evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Pancreatic ductal adenocarcinoma is often classified as operable or inoperable based on how the tumor appears to contact nearby blood vessels on scans. This review argues that anatomy alone may not fully show how aggressive the disease is or whether cancer has already spread in ways that scans cannot detect.
The authors examined research on “biological resectability,” which adds markers of tumor behavior to imaging-based assessment. They describe carbohydrate antigen 19-9 as the most established marker, while circulating tumor DNA and other approaches remain promising but not ready for routine use based on the evidence summarized.
The question reviewed
The researchers conducted a structured narrative review of contemporary evidence on biological resectability in pancreatic ductal adenocarcinoma. They prioritized consensus statements, clinical practice guidelines, meta-analyses, randomized trials, prospective cohorts, and large multicentre studies, then qualitatively classified biomarkers according to their clinical maturity. The abstract does not state the total number of included studies or patients.
What the evidence shows
The review reports that imaging-based anatomical classifications may not identify hidden systemic disease, early recurrence, or which patients are likely to receive meaningful cancer-related benefit from surgery. It identifies carbohydrate antigen 19-9 as the most clinically established biomarker, with interpretation affected by biliary conditions, response to treatment, and multidisciplinary assessment. Circulating tumor DNA may help with molecular staging and recurrence-risk assessment, but prospective interventional validation remains limited. Transcriptomic subtypes, PET-derived measures, radiomics, and combined biomarker models are described as providing additional biological information but as largely investigational.
Who this may apply to
This review is relevant to people with pancreatic ductal adenocarcinoma because it discusses how imaging findings and biological markers may be considered in treatment planning. However, it does not establish that any particular biomarker improves outcomes, and the findings should not be treated as applying uniformly to every patient.
Why it matters
The review highlights why the appearance of a pancreatic tumor on scans may not provide a complete picture of disease behavior. In principle, combining anatomical information with biological markers could help researchers and clinicians study treatment sequencing and patient selection more precisely. However, this review does not show that biomarker-guided decisions improve survival or other patient outcomes, and it does not establish a routine test strategy. The findings concern human cancer research; no animal or laboratory findings are presented as evidence here, although the review may include studies using different research methods in its cited literature that are not detailed in the abstract.
Limitations & evidence assessment
The review is narrative and qualitatively synthesizes selected studies rather than providing a pooled estimate of effects. The abstract does not report the number or detailed characteristics of included studies, and it does not describe a formal risk-of-bias assessment. The review notes that prospective validation, standardized testing, and biomarker-guided clinical trials are still limited, especially for circulating tumor DNA, molecular subtypes, PET measures, radiomics, and combined models. These limitations mean the findings describe an evolving research area rather than establishing a proven decision rule.
Why this evidence level: This is a structured narrative review that considers guidelines, consensus statements, trials, observational studies, and other research. Because the evidence was synthesized qualitatively rather than through a formal systematic review or meta-analysis, and several biomarkers remain investigational, the overall level is rated moderate rather than high.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Annali Italiani di Chirurgia · 2026 · DOI: 10.62713/aic.4732
This systematic review examined randomized human trials of concurrent chemotherapy and radiation for locally advanced head and neck, cervical, esophageal, and non-small-cell lung cancers. Across the included trials, combined treatment was reported to provide better overall survival than radiation alone, but it also caused more severe short-term side effects. The review did not provide enough information in its abstract to show how many trials or patients were included.
Researchers pooled results from seven human studies comparing multiple-staged with single-stage removal and reconstruction of congenital melanocytic nevi, sometimes called congenital moles. Staged surgery was associated with fewer major wound complications and recurrences, as well as slightly shorter and narrower scars, but the studies did not find a clear difference in cosmetic or overall patient satisfaction.
A cluster-randomized human study in 210 adults with recently detected stage 1 hypertension in Uzbekistan compared salt-sensitivity testing followed by assigned medication choices with conventional management. After 12 weeks, more participants in the testing-guided group reached the study's blood pressure target, although the study was small, short, and conducted in only three primary care centers.
